Document is current
Any future updates will be listed below
-
Authors
Yusufova, Nevin
Kloetgen, Andreas https://orcid.org/0000-0003-0991-4442
Teater, Matt
Osunsade, Adewola https://orcid.org/0000-0001-6340-8765
Camarillo, Jeannie M. https://orcid.org/0000-0001-9699-0931
Chin, Christopher R. https://orcid.org/0000-0002-2140-3197
Doane, Ashley S. https://orcid.org/0000-0002-1489-1786
Venters, Bryan J.
Portillo-Ledesma, Stephanie
Conway, Joseph
Phillip, Jude M.
Elemento, Olivier
Scott, David W.
Béguelin, Wendy
Licht, Jonathan D. https://orcid.org/0000-0002-3942-1369
Kelleher, Neil L. https://orcid.org/0000-0002-8815-3372
Staudt, Louis M.
Skoultchi, Arthur I. https://orcid.org/0000-0001-5096-8077
Keogh, Michael-Christopher https://orcid.org/0000-0002-2219-8623
Apostolou, Effie https://orcid.org/0000-0002-8111-0863
Mason, Christopher E. https://orcid.org/0000-0002-1850-1642
Imielinski, Marcin https://orcid.org/0000-0002-2211-4741
Schlick, Tamar
David, Yael https://orcid.org/0000-0003-1696-0025
Tsirigos, Aristotelis https://orcid.org/0000-0002-7512-8477
Allis, C. David
Soshnev, Alexey A. https://orcid.org/0000-0002-1713-3470
Cesarman, Ethel https://orcid.org/0000-0003-3303-6299
Melnick, Ari M. https://orcid.org/0000-0002-8074-2287
- License Information
-
More Information
Article History
Received: 2 January 2020
Accepted: 8 October 2020
First Online: 9 December 2020
Competing interests
: A.M.M. has research funding from Janssen Pharmaceuticals, Sanofi and Daiichi Sankyo, has consulted for Epizyme and Constellation and is on the advisory board for KDAC Pharma. A.M.M. has also been on advisory boards for BMS and ExoTherapeutics. N.L.K. is a consultant for Thermo Fisher Scientific. C.D.A is a co-founder of Chroma Therapeutics and Constellation Pharmaceuticals, and a Scientific Advisory Board member of EpiCypher. EpiCypher is a commercial developer of the CUTANA CUT&RUN platform. M.I. has received consultancy fees from Novartis Venture Fund outside of the scope of the work. The remaining authors declare no competing interests.
